At-Home Self-Collection Device for Cervical Cancer Screening Gets FDA Approval
Teal Health has received FDA approval for the Teal Wand, a prescription-based self-collection device for cervical cancer screening.
Teal Health has received FDA approval for the Teal Wand, a prescription-based self-collection device for cervical cancer screening.
In this episode of Clinical Lab Chat, Jeff Andrews, MD, FRCSC, of BD, returns to discuss BD and MD Anderson’s HPV self-collection study.
OncoHost will highlight the PROphet platform's capability to predict benefits from therapies across various cancers.
Researchers discovered that lymphatic fluid from surgical drains could inform precise treatments for patients with head and neck cancer.
Read MoreThe $3.6 million grant aims to further research on a noninvasive diagnostic biomarker panel for the early detection of oropharyngeal cancer.
Read MoreRoche announced the U.S. FDA approved the cobas HPV test for use on its next-generation cobas 5800 molecular instrument.
Read MoreAbbott received FDA approval for its molecular HPV screening solution for its Alinity m family of diagnostic assays.
Read MoreScientists at the Montefiore Einstein Cancer Center developed a test for detecting a type of cervical cancer that Pap tests often miss.
Read MoreNew tests offer clinical and technological perspectives on how to measure if recurrence is happening earlier than current blood tests allow.
Read MoreSelf-collection could be an effective way to increase access to screening for cervical cancer, diagnosing the disease earlier.
Read MoreSelf-collected tests performed similarly to provider-collected tests for detecting common sexually transmitted infections (STIs).
Read MoreFor women over the age of 65 who have never had a high-risk HPV test, a “catch up” test may improve cervical cancer prevention.
Read MoreWith the goal of improving cervical cancer care, AACC published a new guidance document with expert recommendations on detecting this cancer.
Read MoreVirax Biolabs announced the distribution of HPV test kits with shipments anticipated in the first quarter of 2023.
Read MoreThe triage approach offers women and labs a more efficient and effective way to diagnose and manage cervical cancer earlier.
Read MoreAs women catch up on missed cervical cancer screenings, more tools are needed that will be able to identify cancer-causing HPV genotypes.
Read MoreTotal Testing Solutions announced a partnership with OmniPathology to offer oral HPV testing in the Los Angeles area.
Read MoreA new study found that routine screening for, and removal of, precancerous anal lesions can significantly reduce the risk of anal cancer.
Read More